Predicting HSV-1 Reactivation in Critically Ill Patients Using Bronchoscopy
Performance of a Bronchoscopic Score for Prediction of Tracheobronchial Herpes Simplex Virus Type 1 (HSV-1) Reactivation
This study is testing if a special scoring system used during a lung exam can help predict when critically ill patients might have a reactivation of the Herpes Simplex Virus Type 1.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Muenster Academic / other |
| Locations | 1 site (Münster) |
| Trial ID | NCT05331417 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the ability to predict reactivation of Herpes Simplex Virus Type 1 (HSV-1) in critically ill patients through a standardized bronchoscopic score assessing tracheobronchial inflammation. The score evaluates mucosal redness, swelling, and vulnerability, with values ranging from 0 to 6 assigned by an experienced ICU physician. The presence of HSV-1 reactivation is confirmed using quantitative PCR analysis of bronchoalveolar lavage fluid, alongside secondary analyses of immunocompetence markers. The study aims to enhance understanding of HSV-1 reactivation in the context of tracheobronchitis and its implications for patient care.
Who should consider this trial
Good fit: Ideal candidates are critically ill adult patients aged 18 years or older who require bronchoscopy during their ICU stay.
Not a fit: Patients with solid organ transplants, current COVID-19 infection, or severe immunodeficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction and management of HSV-1 reactivation in critically ill patients, potentially reducing ICU stay and mechanical ventilation duration.
How similar studies have performed: While the approach of using bronchoscopic scoring for predicting viral reactivation is innovative, similar studies have not been widely reported, indicating this may be a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1. Adult patients (age ≥18 years) 2. Indication for bronchoscopy during intensive care unit stay 3. Written informed consent Exclusion Criteria: * 1. Solid organ transplantation 2. Present coronavirus disease 2019 (COVID-19) infection 3. Previous bronchoscopy during present hospital stay 4. Pregnancy 5. Known primary or secondary severe immunodeficiency
Where this trial is running
Münster
- University Hospital Münster — Münster, Germany (Recruiting)
Study contacts
- Study coordinator: Christian Ertmer, MD
- Email: ertmer@anit.uni-muenster.de
- Phone: +49-251-8347255
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.